Targeted deletion of miR-139-5p activates MAPK, NF-κB and STAT3 signaling and promotes intestinal inflammation and colorectal cancer

FEBS Journal

Volumn 283, Issue 8, 2016, Pages 1438-1452

  Zou, Fangyuan ^a   Mao, Rurong ^a   Yang, Liyan ^a   Lin, Shengchao ^a   Lei, Kecheng ^a   Zheng, Yuanhong ^a   Ding, Yue ^a   Zhang, Peng ^a   Cai, Guoxiang ^b,c   Liang, Xin ^a   Liu, Jianwen ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

acute colitis; apoptosis; colitis associated colorectal cancer; miR 139 5p; proliferation

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MIR 139 5P; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; UNCLASSIFIED DRUG; MESSENGER RNA; MIRN139 MICRORNA, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; ENTERITIS; ENZYME ACTIVATION; GENE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAP1B GENE; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL TRANSFORMATION; CHEMICALLY INDUCED; COLITIS; COLORECTAL NEOPLASMS; COMPLICATION; ENZYME IMMUNOASSAY; GENETICS; INFLAMMATION; INTESTINE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; COLITIS; COLORECTAL NEOPLASMS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; INTESTINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84960155737     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13678     Document Type: Article

References (53)

1. Feagins LA, Souza RF, &, Spechler SJ, (2009) Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 6, 297-305.
2. Itzkowitz SH, &, Yio X, (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287, G7-G17.
3. Lakatos PL, &, Lakatos L, (2008) Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 14, 3937-3947.
4. Grivennikov SI, Greten FR, &, Karin M, (2010) Immunity, inflammation, and cancer. Cell 140, 883-899.
5. Quante M, &, Wang TC, (2008) Inflammation and stem cells in gastrointestinal carcinogenesis. Physiology (Bethesda) 23, 350-359.
6. Shen K, Mao R, Ma L, Li Y, Qiu Y, Cui D, Le V, Yin P, Ni L, &, Liu J, (2014) Post-transcriptional regulation of the tumor suppressor miR-139-5p and a network of miR-139-5p-mediated mRNA interactions in colorectal cancer. FEBS J 281, 3609-3624.
7. Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q, &, Liu J, (2012) MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol 84, 320-330.
8. Guo H, Hu X, Ge S, Qian G, &, Zhang J, (2012) Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation. Int J Biochem Cell Biol 44, 1465-1472.
9. Zhang L, Dong Y, Zhu N, Tsoi H, Zhao Z, Wu CW, Wang K, Zheng S, Ng SS, Chan FK, et al,. (2014) microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer. Mol Cancer 13, 124.
10. Song M, Yin Y, Zhang J, Zhang B, Bian Z, Quan C, Zhou L, Hu Y, Wang Q, Ni S, et al,. (2014) MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1. Protein Cell 5, 851-861.
11. Luo HN, Wang ZH, Sheng Y, Zhang Q, Yan J, Hou J, Zhu K, Cheng Y, Xu YL, Zhang XH, et al,. (2014) MiR-139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells. Med Oncol 31, 789.
12. Krishnan K, Steptoe AL, Martin HC, Pattabiraman DR, Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Vlassov A, et al,. (2013) miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA 19, 1767-1780.
13. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K, &, Ng IO, (2011) The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 140, 322-331.
14. Fan Q, He M, Deng X, Wu WK, Zhao L, Tang J, Wen G, Sun X, &, Liu Y, (2013) Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma. Cell Biochem Funct 31, 319-324.
15. Gu W, Li XM, &, Wang J, (2014) miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway. Oncol Rep 31, 397-404.
16. Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, Zhao J, Meng YL, Ren XL, Wang T, et al,. (2011) HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 141, e2076.
17. Liu R, Yang M, Meng Y, Liao J, Sheng J, Pu Y, Yin L, &, Kim SJ, (2013) Tumor-suppressive function of miR-139-5p in esophageal squamous cell carcinoma. PLoS One 8, e77068.
18. Li RY, Chen LC, Zhang HY, Du WZ, Feng Y, Wang HB, Wen JQ, Liu X, Li XF, Sun Y, et al,. (2013) MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. CNS Neurosci Ther 19, 477-483.
19. Neufert C, Becker C, &, Neurath MF, (2007) An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2, 1998-2004.
20. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, &, Mori H, (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 94, 965-973.
21. Thaker AI, Shaker A, Rao MS, &, Ciorba MA, (2012) Modeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS). J Vis Exp doi: 10.3791/4100.
22. Chen GY, Liu M, Wang F, Bertin J, &, Nunez G, (2011) A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 186, 7187-7194.
23. Zaki MH, Vogel P, Malireddi RK, Body-Malapel M, Anand PK, Bertin J, Green DR, Lamkanfi M, &, Kanneganti TD, (2011) The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 20, 649-660.
24. Turini ME, &, DuBois RN, (2002) Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53, 35-57.
25. Mantovani A, (2010) Molecular pathways linking inflammation and cancer. Curr Mol Med 10, 369-373.
26. Hill DA, &, Artis D, (2010) Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol 28, 623-667.
27. Coussens LM, &, Werb Z, (2002) Inflammation and cancer. Nature 420, 860-867.
28. Bos JL, de Rooij J, &, Reedquist KA, (2001) Rap1 signalling: adhering to new models. Nat Rev Mol Cell Biol 2, 369-377.
29. Ribeiro-Neto F, Urbani J, Lemee N, Lou L, &, Altschuler DL, (2002) On the mitogenic properties of Rap1b: cAMP-induced G(1)/S entry requires activated and phosphorylated Rap1b. Proc Natl Acad Sci U S A 99, 5418-5423.
30. Stork PJS, (2003) Does Rap1 deserve a bad Rap? Trends Biochem Sci 28, 267-275.
31. Fang JY, &, Richardson BC, (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6, 322-327.
32. Buchanan FG, &, DuBois RN, (2006) Connecting COX-2 and Wnt in cancer. Cancer Cell 9, 6-8.
33. Smith WL, DeWitt DL, &, Garavito RM, (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69, 145-182.
34. Fan Y, Mao R, &, Yang J, (2013) NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 4, 176-185.
35. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, &, Ben-Neriah Y, (2004) NF-kappa B functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466.
36. Karin M, (2006) NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 45, 355-361.
37. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, et al,. (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21, 491-501.
38. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, &, Pestell RG, (2001) NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12, 73-90.
39. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, et al,. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102.
40. Hanahan D, &, Weinberg RA, (2000) The hallmarks of cancer. Cell 100, 57-70.
41. Yu H, Kortylewski M, &, Pardoll D, (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7, 41-51.
42. Biswas A, Wilmanski J, Forsman H, Hrncir T, Hao L, Tlaskalova-Hogenova H, &, Kobayashi KS, (2011) Negative regulation of Toll-like receptor signaling plays an essential role in homeostasis of the intestine. Eur J Immunol 41, 182-194.
43. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, Abramowicz M, Van Gossum A, &, Devière J, (2004) Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53, 987-992.
44. Doan HQ, Bowen KA, Jackson LA, &, Evers BM, (2009) Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res 29, 2473-2478.
45. Onnureddy K, Onteru SK, &, Singh D, (2015) IGF-1 attenuates LPS induced pro-inflammatory cytokines expression in buffalo (Bubalus bubalis) granulosa cells. Mol Immunol 64, 136-143.
46. Sinha S, Koul N, Dixit D, Sharma V, &, Sen E, (2011) IGF-1 induced HIF-1α-TLR9 cross talk regulates inflammatory responses in glioma. Cell Signal 23, 1869-1875.
47. Tserel L, Runnel T, Kisand K, Pihlap M, Bakhoff L, Kolde R, Peterson H, Vilo J, Peterson P, &, Rebane A, (2011) MicroRNA expression profiles of human blood monocyte-derived dendritic cells and macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4. J Biol Chem 286, 26487-26495.
48. Wang J, Lee S, Teh CE, Bunting K, Ma L, &, Shannon MF, (2009) The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. Int Immunol 21, 227-235.
49. Tu L, Fang TC, Artis D, Shestova O, Pross SE, Maillard I, &, Pear WS, (2005) Notch signaling is an important regulator of type 2 immunity. J Exp Med 202, 1037-1042.
50. Wellen KE, &, Hotamisligil GS, (2005) Inflammation, stress, and diabetes. J Clin Invest 115, 1111-1119.
51. Sierra RA, Thevenot P, Raber PL, Cui Y, Parsons C, Ochoa AC, Trillo-Tinoco J, Del Valle L, &, Rodriguez PC, (2014) Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer. Cancer Immunol Res 2, 800-811.
52. Kilkenny C, Browne W, Cuthill IC, Emerson M, &, Altman DG, (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. Brit J Pharmacol 160, 1577-1579.
53. Chen GY, Shaw MH, Redondo G, &, Nunez G, (2008) The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 68, 10060-10067.